We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Tenofovir in Chronic Hepatitis B With Mild ALT Elevation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01522625
Recruitment Status : Active, not recruiting
First Posted : January 31, 2012
Last Update Posted : March 21, 2017
Gilead Sciences
Taipei Institute of Pathology
Information provided by (Responsible Party):
Tu, Yuan-Kun, E-DA Hospital

January 27, 2012
January 31, 2012
March 21, 2017
January 2012
January 2018   (Final data collection date for primary outcome measure)
Severity of hepatic necroinflammation and fibrosis [ Time Frame: Within one month after completion of antiviral therapy ]
Primary outcome is the severity of necroinflammation and fibrosis in liver tissue as evaluated by Knodell and Ishak scoring system
Same as current
Complete list of historical versions of study NCT01522625 on ClinicalTrials.gov Archive Site
  • Undetectable hepatitis B viral DNA [ Time Frame: Within one month after completion of antiviral therapy ]
    HBV DNA viral DNA not detected in serum
  • Normalization of serum alanine aminotransferase [ Time Frame: Within one month after completion of antiviral therapy ]
    serum ALT <40 IU/mL
  • Serum level of HBsAg [ Time Frame: Within one month after completion of antiviral therapy ]
    quantification of serum HBV serface antigen
  • Serious adverse reaction [ Time Frame: Within one month after completion of antiviral therapy ]
    Defined as death, life threatening event, permanent or temporary disability, and hospitalization
Same as current
Not Provided
Not Provided
Tenofovir in Chronic Hepatitis B With Mild ALT Elevation
Efficacy of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients With High Viral Load But Slight Aminotransferase Elevation
This study aims to clarify whether patients with chronic hepatitis B with high viral load will benefit from oral antiviral therapy despite only mildly elevated serum liver enzyme.
Chronic hepatitis B (CHB) is a serious disease in Taiwan, leading to substantial morbidity and mortality including hepatic failure, liver cirrhosis, and hepatocellular carcinoma (HCC). Recently a large body of evidence supports that high level of serum HBV DNA is an independent risk factor for late complications in CHB patients. Nucleos(t)ide analogues (NUC) are effective antiviral therapy that can potently inhibit replication of hepatitis B virus (HBV), and has been widely used in management of patients with CHB. Current practice guidelines recommend using serum alanine aminotransferase (ALT) > 2 times of the upper limit of normal (ULN) as the prerequisite to initiate antiviral therapy in compensated CHB patients without liver cirrhosis. However, serum ALT level does not exactly correlate with serum HBV DNA or liver tissue injury. Whether antiviral therapy improves outcomes of patients with slightly elevated ALT (i.e. 1-2 folds of ULN) remains unknown.
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Chronic Hepatitis B
  • Drug: tenofovir disoproxil fumarate 300mg per day
    tenofovir disoproxil fumarate 300mg per day for 3 years
    Other Name: Viread® (Gilead Sciences Inc)
  • Drug: Placebo
    Placebo, identical to TDF in appearance, once daily for 3years
  • Experimental: TDF
    tenofovir disoproxil fumarate (TDF) 300mg
    Intervention: Drug: tenofovir disoproxil fumarate 300mg per day
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Active, not recruiting
December 2018
January 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • age between 25 to 70 years,
  • serum HBsAg positivity for more than 6 months,
  • positive or negative serum HBeAg,
  • serum HBV DNA more than 2,000 IU/mL,
  • highest serum ALT > 1 fold of ULN, but < 2 X ULN on at least two occasions (≧ 3 months apart) in the preceding one year,

Exclusion Criteria:

  • co-infection with HIV, HCV, or HDV,
  • previous exposure to HBV antiviral therapy for more than 12 weeks,
  • presence of cirrhosis on histopathology,
  • hepatic decompensation defined as serum bilirubin > 2mg/dl and prolonged prothrombin time > 3 seconds,
  • concurrent malignant diseases including hepatocellular carcinoma,
  • severe co-morbidity with life expectancy < 1year,
  • pregnant or lactating women,
  • organ transplantation except cornea or hair transplant,
  • suspected or confirmed chronic liver diseases from etiologies other than HBV (e.g. alcoholic hepatitis, Wilson disease, Hemochromatosis…etc),
  • serum creatinine >1.5mg/dL
Sexes Eligible for Study: All
25 Years to 70 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Tu, Yuan-Kun, E-DA Hospital
E-DA Hospital
  • Gilead Sciences
  • Taipei Institute of Pathology
Principal Investigator: Yao-Chun Hsu, MD, MSc E-Da Hospital, Kaohsiung, Taiwan
Study Chair: Jaw-Town Lin, MD, PhD National Taiwan University
E-DA Hospital
March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP